Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

Breast Cancer Research and Treatment

Volumn 116, Issue 1, 2009, Pages 131-143

  Pentheroudakis, George ^a   Kalogeras, Konstantine T ^b,c   Wirtz, Ralph M ^d   Grimani, Irene ^c   Zografos, George ^e   Gogas, Helen ^e   Stropp, Udo ^d   Pectasides, Dimitrios ^f   Skarlos, Dimosthenis ^g   Hennig, Guido ^d   Samantas, Epaminondas ^h   Bafaloukos, Dimitrios ^g   Papakostas, Pavlos ⁱ   Kalofonos, Haralabos P ^j   Pavlidis, Nicholas ^a   Fountzilas, George ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d SIEMENS AG   (Germany)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^g METROPOLITAN HOSPITAL   (Greece)

^h AGII ANARGIRI CANCER HOSPITAL   (Greece)

ⁱ HIPPOKRATION HOSPITAL   (Greece)

^j UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

Breast cancer; Estrogen receptor; MAP Tau; Microtubule; Predictive value; Progesterone receptor

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN; GRANULOCYTE COLONY STIMULATING FACTOR; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAU PROTEIN;

ADJUVANT THERAPY; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC RISK; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEPTOR GENE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TAU PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649418382     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0144-9     Document Type: Article

References (36)

1. EBCTC Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
2. J Bonneterre B Thurlimann JFR Robertson 2000 Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 post-menopausal women: results of the Tamoxifen or Arimidex Randomised Group Efficacy and Tolerability study J Clin Oncol 18 3748 3757 (Pubitemid 30846220)
3. H Mouridsen M Gershanovich Y Sun 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2596 2606 (Pubitemid 32451796)
4. IC Henderson AJ Patek 1998 The relationship between prognostic and predictive factors in the management of breast cancer Breast Cancer Res Treat 52 261 288 (Pubitemid 29056100)
5. M Trudeau F Charbonneau K Gelmon 2005 Selection of adjuvant chemotherapy for treatment of node-positive breast cancer Lancet Oncol 6 886 898 (Pubitemid 41614801)
6. L Pusztai C Mazouni K Anderson Y Wu F Symmans 2006 Molecular classification of breast cancer: limitations and potential Oncologist 11 868 877 (Pubitemid 44373759)
7. JM Harvey GM Clark CK Osborne 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 (Pubitemid 29220854)
8. LJ Layfield N Goldstein KR Perkinson 2003 Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status Breast J 9 257 259 (Pubitemid 36627180)
9. A Rhodes B Jasani DM Barnes 2000 Reliability of immunohistochemical demonstration of estrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems J Clin Pathol 53 125 130 (Pubitemid 30075056)
10. T Rudiger H Hofler HH Kreipe 2002 Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists Am J Surg Pathol 26 873 882 (Pubitemid 34747639)
11. Bianchini G, Zambetti M, Pusztai L et al (2007) Use of estrogen receptor expression by quantitative RT-PCR to identify an ER-negative subgroup by IHC who might benefit from hormonal therapy. 2007 Breast Cancer Symposium; Abstract 106
12. Badve SS, Baehner FL, Gray R et al (2007) ER and PR assessment in ECOG 2197: comparison of locally determined IHC with centrally determined IHC and quantitative RT-PCR. 2007 Breast Cancer Symposium; Abstract 87
13. Y Gong K Yan K Anderson C Sotiriou F Andre 2007 Determination of estrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study Lancet Oncol 8 203 211 (Pubitemid 46304454)
14. KMR Bhat V Setaluri 2007 Microtubule-associated proteins as targets in cancer chemotherapy Clin Cancer Res 13 2849 2854 (Pubitemid 46849557)
15. G Fountzilas D Skarlos U Dafni H Gogas E Briasoulis 2005 Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomised phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 16 1762 1771 (Pubitemid 41631238)
16. JR Landis GG Koch 1977 The measurement of observer agreement for categorical data Biometrics 33 159 174 (Pubitemid 8054849)
17. Hudis TL et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127-2132
18. LM McShane DG Altman W Sauerbrei 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 (Pubitemid 46260161)
19. NS Goldstein M Ferkowicz E Odish 2003 Minimum formalin fixation time for consistent estrogen receptor immunocytochemical staining of invasive breast carcinoma Am J Clin Pathol 120 86 92 (Pubitemid 37046374)
20. A Rhodes 2003 Quality assurance in immunohistochemistry Am J Surg Pathol 27 1284 1285
21. KV Morris 2008 RNA-mediated transcriptional gene silencing in human cells Curr Top Microbiol Immunol 320 211 224
22. M Ravo M Mutarelli L Ferraro OM Grober O Paris 2008 Quantitative expression profiling of highly degraded RNA from formalin-fixed paraffin-embedded breast tumour biopsies by oligonucleotide microarrays Lab Invest 88 430 440
23. Van Maldegem F, De Wit M, Morsink F, Musler A, Weegenaar J et al (2008) Effects of processing delay, formalin fixation and immunohistochemistry on RNA recovery from formalin-fixed paraffin-embedded tissue sections. Diagn Mol Pathol Jan 28 (Epub ahead of print)
24. L Pusztai M Ayers J Stec E Clark K Hess 2003 Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumours Clin Cancer Res 9 2406 2415 (Pubitemid 36842079)
25. S Paik S Shak G Tang 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817 2826 (Pubitemid 40051905)
26. WF Symmans C Sotiriou SK Anderson 2005 Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy Breast Cancer Res Treat 94 suppl 1 308a
27. SE Webb SK Roberts SR Needham CJ Tynan DJ Rolfe 2008 Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity EGFR in A431 cells Biophys J 94 803 819 (Pubitemid 351162449)
28. J Yasuda Y Hayashizaki 2008 The RNA continent Adv Cancer Res 99 77 112 (Pubitemid 350137253)
29. S Ramaswamy P Tamayo R Rifkins 2001 Multiclass cancer diagnosis using tumour gene expression signatures Proc Natl Acad Sci USA 98 15149 15154 (Pubitemid 34013984)
30. M West C Blanchette H Dressman E Huang S Ishida 2001 Predicting the clinical status of human breast cancer by using gene expression profiles Proc Natl Acad Sci USA 98 11462 11467 (Pubitemid 32928751)
31. A Matsuno S Takekoshi N Sanno H Utsunomiya Y Ohsugi 1997 Modulation of protein kinases and microtubule-associated proteins and changes in ultrastructure in female rat pituitary cells: effects of estrogen and bromocriptine J Histochem Cytochem 45 805 813 (Pubitemid 27248796)
32. MA Jordan L Wilson 2004 Microtubules as a target for anticancer drugs Nat Rev Cancer 4 253 265 (Pubitemid 38525281)
33. S Kar J Fan MJ Smith M Goedert LA Amos 2003 Repeat motifs of Tau bind to the insides of microtubules in the absence of taxol EMBO J 22 70 77 (Pubitemid 36091270)
34. R Rouzier R Rajan P Wagner KR Hess DL Gold 2005 Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer PNAS 102 8315 8320 (Pubitemid 40800086)
35. F Andre C Hatzis K Anderson S Sotiriou C Mazouni 2007 Microtubule-associated protein tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen-receptor positive breast cancer Clin Cancer Res 13 2061 2067 (Pubitemid 46649873)
36. A Rody T Karn R Gatje A Ahr C Solbach 2007 Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumour response Breast 16 86 93 (Pubitemid 46172862)